These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 30482243)

  • 1. Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma.
    Oliveira LJC; Gongora ABL; Barbosa FG; Dos Anjos CH; Munhoz RR
    J Immunother Cancer; 2018 Nov; 6(1):130. PubMed ID: 30482243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy.
    Fujimoto D; Yoshioka H; Kataoka Y; Morimoto T; Hata T; Kim YH; Tomii K; Ishida T; Hirabayashi M; Hara S; Ishitoko M; Fukuda Y; Hwang MH; Sakai N; Fukui M; Nakaji H; Morita M; Mio T; Yasuda T; Sugita T; Hirai T
    J Thorac Oncol; 2019 Mar; 14(3):468-474. PubMed ID: 30468872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [A Case of Myocardial and Cutaneous Metastases of Squamous Cell Lung Cancer Post Left Pneumonectomy and Radical Surgery for Cutaneous Metastasis during Nivolumab Therapy].
    Watanabe I; Kanauchi N; Watanabe H
    Gan To Kagaku Ryoho; 2018 Oct; 45(10):1441-1444. PubMed ID: 30382041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of unresectable cutaneous squamous cell carcinoma with pembrolizumab.
    Venkatesh S; Al-Haseni A; Sahni D
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31377718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer.
    Katz SI; Hammer M; Bagley SJ; Aggarwal C; Bauml JM; Thompson JC; Nachiappan AC; Simone CB; Langer CJ
    J Thorac Oncol; 2018 Jul; 13(7):978-986. PubMed ID: 29738824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-PD1 in Merkel cell carcinoma and cutaneous squamous cell carcinoma, description of five cases and recent data from the literature.
    Sellah D; Saint-Jean M; Peuvrel L; Khammari A; Quéreux G; Dréno B
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):e159-e161. PubMed ID: 30451326
    [No Abstract]   [Full Text] [Related]  

  • 7. PD-1 blockade in patients with advanced cutaneous squamous-cell carcinoma and concurrent chronic lymphocytic leukaemia : a case series and literature review.
    Eglmeier J; Debus D; Schultz ES
    Eur J Dermatol; 2020 Feb; 30(1):69-71. PubMed ID: 32250263
    [No Abstract]   [Full Text] [Related]  

  • 8. Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    Swami U; Smith M; Zhang J
    J Thorac Oncol; 2018 Sep; 13(9):e183-e184. PubMed ID: 30166022
    [No Abstract]   [Full Text] [Related]  

  • 9. Successful treatment of unresectable recurrent cutaneous squamous cell carcinoma of the scalp with meningeal invasion with nivolumab monotherapy.
    Fujimura T; Kambayashi Y; Tono H; Lyu C; Ohuchi K; Hashimoto A; Aiba S
    Dermatol Ther; 2020 Jul; 33(4):e13672. PubMed ID: 32449226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Immunotherapy for Advanced Cutaneous Squamous Cell Carcinoma.
    Ogata D; Tsuchida T
    Curr Treat Options Oncol; 2019 Mar; 20(4):30. PubMed ID: 30874952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab: A case report.
    Sarfaty M; Moore A; Dudnik E; Peled N
    Medicine (Baltimore); 2017 Jan; 96(4):e5951. PubMed ID: 28121940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
    Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
    Front Immunol; 2018; 9():1769. PubMed ID: 30108590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different responses to nivolumab therapy between primary and metastatic tumors in a patient with recurrent hypopharyngeal squamous cell carcinoma.
    Sato K; Ono T; Sato F; Kawahara A; Azuma K; Kawaguchi T; Akiba J; Umeno H
    Oral Oncol; 2020 Feb; 101():104366. PubMed ID: 31300273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to PD1 inhibition in conventional chondrosarcoma.
    Wagner MJ; Ricciotti RW; Mantilla J; Loggers ET; Pollack SM; Cranmer LD
    J Immunother Cancer; 2018 Sep; 6(1):94. PubMed ID: 30253794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme.
    De Giorgi U; Cartenì G; Giannarelli D; Basso U; Galli L; Cortesi E; Caserta C; Pignata S; Sabbatini R; Bearz A; Buti S; Lo Re G; Berruti A; Bracarda S; Cognetti F; Rastelli F; Fornarini G; Porta C; Turci D; Sternberg CN; Procopio G;
    BJU Int; 2019 Jan; 123(1):98-105. PubMed ID: 29956884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cetuximab-radiotherapy combination in the management of locally advanced cutaneous squamous cell carcinoma.
    Joseph K; Alkaabi K; Warkentin H; Ghosh S; Jha N; Smylie M; Walker J
    J Med Imaging Radiat Oncol; 2019 Apr; 63(2):257-263. PubMed ID: 30549229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appearance of New Cutaneous Superficial Basal Cell Carcinomas during Successful Nivolumab Treatment of Refractory Metastatic Disease: Implications for Immunotherapy in Early Versus Late Disease.
    Cohen PR; Kato S; Goodman AM; Ikeda S; Kurzrock R
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28788102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810.
    Falchook GS; Leidner R; Stankevich E; Piening B; Bifulco C; Lowy I; Fury MG
    J Immunother Cancer; 2016; 4():70. PubMed ID: 27879972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Durable intracranial and extracranial response to nivolumab with appearance of secondary resistance in a heavily pretreated patient with head and neck cancer.
    Cabezas-Camarero S; García-Barberán V; Sáiz-Pardo Sanz M; Cabrera-Martín MN; Gimeno-Hernández J; Pérez-Segura P
    Head Neck; 2019 Jun; 41(6):E86-E92. PubMed ID: 30652379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma.
    Noda T; Komune N; Yasumatsu R; Tsuchihashi NA; Tamae A; Matsumoto N; Sato K; Uchi R; Koike K; Wakasaki T; Tanaka R; Nakagawa T
    Auris Nasus Larynx; 2020 Oct; 47(5):864-869. PubMed ID: 32446629
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.